Jardiance is a medicine used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease. In type 2 diabetes, Jardiance is used in adults whose condition is not controlled well enough. It is used with appropriate diet and exercise in patients who cannot take metformin (another treatment for diabetes). It can also be used as an ‘add-on’ treatment to other diabetes medicines. In chronic heart failure (a condition in which the heart does not pump blood around the body as well as it should), Jardiance is used in adults to treat symptoms of the disease. Jardiance is also used in adults with chronic kidney disease. Jardiance contains the active substance empagliflozin.
Therapeutic Indication
### Therapeutic indication **Type 2 diabetes mellitus** Jardiance is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance - in addition to other medicinal products for the treatment of diabetes For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. **Heart failure** Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure. **Chronic kidney disease** Jardiance is indicated in adults for the treatment of chronic kidney disease.
Therapeutic Area (MeSH)
ATC Code
A10BK03
ATC Item
empagliflozin
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| empagliflozin | N/A | 恩格列净 |
EMA Name
Jardiance
Medicine Name
Jardiance
Aliases
N/A
